Insights

Personalizing cardiovascular disease (CVD) risk assessment improves patient stratification. A similarity measures approach enhanced accuracy in identifying CVD risk, outperforming current tools for Acute Coronary Syndrome patients.

Area of Science:

  • Cardiology
  • Medical Informatics
  • Health Services Research

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality.
  • Current clinical guidelines utilize risk assessment tools for patient CVD risk stratification.
  • Existing tools may exhibit variable performance across different patient populations.

Purpose of the Study:

  • To explore personalized CVD risk assessment strategies.
  • To develop and validate patient grouping methodologies for enhanced risk prediction.
  • To compare the performance of novel personalization methods against existing CVD risk assessment tools.

Main Methods:

  • Developed two patient personalization methods: a clustering approach and a similarity measures approach.
  • Validated these methodologies using data from 460 Portuguese Acute Coronary Syndrome with non-ST segment elevation (ACS-NSTEMI) patients.
  • Evaluated the sensitivity, specificity, and geometric mean of the proposed methods.

Main Results:

  • The similarity measures approach demonstrated superior performance compared to the clustering method.
  • The similarity measures approach achieved a sensitivity of 77.7%, specificity of 63.2%, and geometric mean of 69.7%.
  • These results represent an improvement over the performance of current CVD risk assessment tools (78.5%, 53.2%, 64.4% respectively).

Conclusions:

  • Personalized CVD risk assessment, particularly using similarity measures, can optimize patient stratification.
  • The similarity measures approach offers enhanced accuracy for CVD risk prediction in ACS-NSTEMI patients.
  • This study highlights the potential of tailored risk assessment to improve healthcare strategies for cardiovascular events.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
1.1K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
880
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
975